#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	6382	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2253	643.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1373	1373	C	807	C,G,A	651,3,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	6382	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2253	643.2	0	HET	.	.	.	C542T,A	.	542	542	C	731	731	C	887	C,T,A	509,184,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	6382	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2253	643.2	0	HET	.	.	.	C207T,A	.	207	207	C	396	396	C	631	C,T,A	371,133,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10342	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3720	623.1	0	.	n	.	0	T695C	SNP	695	695	T	1138	1138	C	766	C,G,A,T	594,3,3,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10342	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3720	623.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1780	1780	A	724	A,C	620,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10342	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3720	623.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2414	2414	C	732	C,T,G	593,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10342	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3720	623.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3040	3040	T	672	T,G,A	549,5,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10342	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3720	623.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2488	2488	A	711	A	584	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	460	folP	855	855	100.0	folP.l15.c4.ctg.1	2060	52.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1334	1336	AGC	76;76;76	A,C;G;C,G	66,1;67;65,1	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1200	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3979	70.7	1	SNP	p	S91F	1	.	.	271	273	TTC	920	922	TTC	64;64;64	T,C;T;C,T	53,1;54;58,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1200	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3979	70.7	1	SNP	p	D95G	1	.	.	283	285	GGC	932	934	GGC	72;74;74	G;G;C	60;62;62	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1200	gyrA	2751	2751	100.0	gyrA.l6.c4.ctg.1	3979	70.7	1	SNP	p	G95N	0	.	.	283	285	GGC	932	934	GGC	72;74;74	G;G;C	60;62;62	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	306	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1585	43.2	1	SNP	p	G45D	1	.	.	133	135	GAC	784	786	GAC	85;85;85	G;A;C	66;61;64	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	256	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c30.ctg.1	1218	44.7	0	.	n	.	0	A197.	DEL	197	197	A	668	668	A	93	A	72	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1130	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3042	86.3	1	SNP	p	D86N	1	D86N	NONSYN	256	258	GAC	451	453	AAC	87;87;88	A;A,C;C,T,A	50;60,1;62,1,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1130	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3042	86.3	1	SNP	p	S87I	0	.	.	259	261	AGT	454	456	AGT	88;89;92	A,C;G,C;T,G,C	65,1;65,2;68,1,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1130	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3042	86.3	1	SNP	p	S87R	0	.	.	259	261	AGT	454	456	AGT	88;89;92	A,C;G,C;T,G,C	65,1;65,2;68,1,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1130	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3042	86.3	1	SNP	p	S87W	0	.	.	259	261	AGT	454	456	AGT	88;89;92	A,C;G,C;T,G,C	65,1;65,2;68,1,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1130	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3042	86.3	1	SNP	p	S88P	0	.	.	262	264	TCC	457	459	TCC	92;93;93	T,G;C,T;C	70,1;71,3;76	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1054	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3252	76.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1901	1903	GGC	77;77;77	G;G;C	68;65;62	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.13.001	penA.13.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2507	94.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1480	1482	GCA	165;167;167	G;C;A,C	129;130;128,1	penA.13.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2507	94.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1483	1485	ATC	169;169;168	A,C;T,C,A,G;C,T	132,1;136,1,1,1;134,1	penA.13.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2507	94.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1495	1497	GTG	167;167;167	G,C;T,C,G;G,T	134,1;129,1,1;132,1	penA.13.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2507	94.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1495	1497	GTG	167;167;167	G,C;T,C,G;G,T	134,1;129,1,1;132,1	penA.13.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2507	94.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1999	2001	ACC	117;117;114	A;C;C	85;85;90	penA.13.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2507	94.2	1	SNP	p	A502V	1	.	.	1504	1506	GTG	2053	2055	GTG	78;73;74	G,T,A;T,G;G	67,1,1;56,1;56	penA.13.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2507	94.2	1	SNP	p	V502P	0	.	.	1504	1506	GTG	2053	2055	GTG	78;73;74	G,T,A;T,G;G	67,1,1;56,1;56	penA.13.001:1:1:V502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2507	94.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2176	2178	GGC	74;74;74	G,T,C;G,C,T,A;C,T,G	65,1,1;62,2,1,1;62,3,1	penA.13.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2507	94.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2185	2187	GGC	67;68;68	G;G;C,G	57;50;40,1	penA.13.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.13.001	penA.13.001	1	1	27	1052	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2507	94.2	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2203	2205	TCG	72;72;71	T,G;C,A;G,C,T	44,2;49,1;53,2,1	penA.13.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1292	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3164	90.2	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1449	1451	CCG	95;95;94	C,G,T;C;G,C,A	69,4,2;84;59,6,2	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	430	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1993	49.8	0	.	p	.	0	A17T	NONSYN	49	51	GCA	360	362	ACA	29;29;29	A,G;C;A	21,1;22;22	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	430	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1993	49.8	0	.	p	.	0	S22G	NONSYN	64	66	AGC	375	377	GGC	33;33;33	G;G;C	26;24;25	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	430	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1993	49.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	557	557	C	35	C	28	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	526	porB1b	1041	1041	98.08	porB1b.l15.c17.ctg.1	2125	54.4	0	.	p	.	0	E48G	NONSYN	142	144	GAA	792	794	GGA	73;73;73	G;G;A	56;57;60	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	526	porB1b	1041	1041	98.08	porB1b.l15.c17.ctg.1	2125	54.4	0	.	p	.	0	T87A	NONSYN	259	261	ACT	909	911	GCT	75;75;77	G;C,A;T	58;59,1;58	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	526	porB1b	1041	1041	98.08	porB1b.l15.c17.ctg.1	2125	54.4	0	.	p	.	0	T89S	NONSYN	265	267	ACC	915	917	AGC	77;77;79	A;G;C,G	54;60;57,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	526	porB1b	1041	1041	98.08	porB1b.l15.c17.ctg.1	2125	54.4	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	1077	1079	CAA	105;105;105	C,A;A;A	82,1;82;78	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	526	porB1b	1041	1041	98.08	porB1b.l15.c17.ctg.1	2125	54.4	0	.	p	.	0	V151A	NONSYN	451	453	GTA	1101	1103	GCA	91;91;91	G;C;A,G	71;69;68,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	526	porB1b	1041	1041	98.08	porB1b.l15.c17.ctg.1	2125	54.4	0	.	p	.	0	R187Q	NONSYN	559	561	CGA	1209	1211	CAA	80;80;79	C;A;A	62;62;62	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	526	porB1b	1041	1041	98.08	porB1b.l15.c17.ctg.1	2125	54.4	0	.	p	.	0	N189S	NONSYN	565	567	AAC	1215	1217	AGC	78;78;78	A,G;G;C	61,1;62;62	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	526	porB1b	1041	1041	98.08	porB1b.l15.c17.ctg.1	2125	54.4	0	.	p	.	0	Y212fs	FSHIFT	634	634	T	1284	1284	T	70	T,G	57,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	526	porB1b	1041	1041	98.08	porB1b.l15.c17.ctg.1	2125	54.4	1	SNP	p	G120K	1	.	.	358	360	AAG	1008	1010	AAG	82;82;83	A;A,C;G	69;68,1;70	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	526	porB1b	1041	1041	98.08	porB1b.l15.c17.ctg.1	2125	54.4	1	SNP	p	A121D	1	.	.	361	363	GAC	1011	1013	GAC	84;84;85	G;A;C	70;69;70	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	526	porB1b	1041	1041	98.08	porB1b.l15.c17.ctg.1	2125	54.4	1	SNP	p	D121N	0	.	.	361	363	GAC	1011	1013	GAC	84;84;85	G;A;C	70;69;70	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	3118	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	5082	141.2	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2086	2088	AAT	179;177;177	A;A;T	155;154;153	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	338	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1358	58.6	1	SNP	p	V57M	1	.	.	169	171	ATG	700	702	ATG	99;99;99	A;T;G,T	80;82;81,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
